Role of concentration-dependent plasma protein binding in disopyramide disposition
Tóm tắt
Từ khóa
Tài liệu tham khảo
R. E. Ranney, R. R. Dean, A. Karim, and F. Radzialowski. Disopyramide phosphate: Pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent.Arch. Int. Pharmacodyn. Ther. 191:162–188 (1971).
A. Karim. The pharmacokinetics of norpace.Angiology 26:85–98 (Suppl. 1, Part 2) (1975).
J. W. Ward and S. R. Kinghorn. The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.J. Int. Med. Res. 4:49–53 (Suppl. 1) (1976).
R. E. Rangno, W. Warica, R. I. Ogilvie, and E. Bridges. Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.J. Int. Med. Res. 4:54–58 (Suppl. 1) (1976).
J. Hulting and S. Rosenhamer. Antiarrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmias.J. Int. Med. Res. 4:90–95 (Suppl. 1) (1976).
J. DeGraeve, P. Kremers, and J. E. Sielen. Etude pharmacocinetique et metabolique comparative de la disopyramide administree par voie orale et intraveineuse.Therapie 32:195–204 (1977).
P. H. Hinderling and E. R. Garrett. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.J. Pharmacokin. Biopharm. 4:199–230 (1976).
J. L. Cunningham, D. D. Shen, I. Shudo, and D. L. Azarnoff. The effects of urinepH and plasma protein binding on the renal clearance of disopyramide.Clin. Pharmacokin. 2:373–383 (1977).
P. J. Meffin, S. R. Harapat, and D. C. Harrison. High-pressure liquid Chromatographic analysis of drugs in biological fluids. III. Analysis of disopyramide and its non-N-dealkylated metabolite in plasma and urine.J. Chromatog. 132:503–510 (1977).
J. G. Wagner. A safe method for rapidly achieving plasma concentration plateaus.Clin. Pharmacol. Ther. 16:691–700 (1974).
J. G. Wagner. Linear pharmacokinetic equations attaining direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.J. Pharmacokin. Biopharm. 4:443–66 (1976).
S. Knott and D. Reece. Model Lab Users Documentation, Division of Computer Research Technology Report, National Institutes of Health, Bethesda, Md. September (1971).
H. Boxenbaum, S. Riegelman, and R. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokin. Biopharm. 2:123–148 (1974).
B. B. Brodie, E. W. Lowman, J. J. Burns, P. R. Lee, T. Chenkin, A. Goldman, M. Weiner, and J. M. Steele. Observations on the antirheumatic and physiologic effects of phenyl-butazone (butazolidin) and some comparisons with cortisone.Am. J. Med. 16:181–190 (1954).
R. Runkel, E. Forchielli, H. Sevelius, M. Chaplin, E. Segre. Nonlinear plasma level response to high doses of naproxen.Clin. Pharmacol. Ther. 15:261–266 (1974).
G. T. Tucker, R. N. Boyes, P. O. Bridenbaugh, and D. C. Moore. Binding of amide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties and anesthetic activity.Anesthesiology 32:287–303 (1970).
J. Koch-Weser and E. M. Sellers. Binding of drugs to serum albumin.New Engl. J. Med. 294:311–316 (1976).